BioNTech (BNTX) Stock Forecast for 2025, 2026, 2027. Sell or Buy Prediction







Understanding Accounting and Bookkeeping Services for Business Success

June 10, 2025 Understanding Accounting and Bookkeeping Services for Business Success

Every successful business relies on accurate financial records. From managing cash flow to ensuring compliance with tax regulations, reliable accounting and bookkeeping services…
How much does a Turkish passport cost?

May 27, 2025 How much does a Turkish passport cost?

Turkish citizenship comes with numerous benefits. Once granted, a foreigner can enter 126 countries visa-free, enjoy high-quality healthcare and favorable tax regimes, and…
How Measurement and Mix Modeling Drive Better Business Decisions

May 22, 2025 How Measurement and Mix Modeling Drive Better Business Decisions

In today’s data-driven business landscape, the ability to accurately measure and optimize marketing efforts has become a critical competitive advantage. As marketing evolves,…
Are you making these mistakes when analyzing candlestick patterns?

May 22, 2025 Are you making these mistakes when analyzing candlestick patterns?

Trading is a very popular endeavor these days, and for good reason, as it is widely accessible and allows individuals to generate additional…
Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency

April 23, 2025 Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency

What defines a successful crypto expert? The amount of money earned, the number of luxury cars and international real estate? The presence of…

BioNTech (BNTX) Stock Forecast for 2025, 2026, 2027. Sell or Buy?

Updated: June 22, 2025 (17:21)

Sector: Healthcare

The share price of BioNTech SE (BNTX) now

Latest session on the 20th of June for
BioNTech SE is positive
Trading Volume: 722511
Open: 104.45 /  High: 107.51 /  Low: 104.41
Current value: $106.53
What analysts predict: $131.6
52-week High/Low: $131.49 / $76.53
50-Day Moving Average: $97.66 — support level today
200-Day Moving Average: $107.68 — resistance level today

News Impact Analyzer

Full report
This Week
Na Impact: Na News: Na
Previous Week
Bullish Impact: 2.25 News: 5 (2/2/1)
Two Weeks Ago
Bullish Impact: 1.13 News: 3 (1/1/1)
Three Weeks Ago
Bearish Impact: 5 News: 1

Analysts predictions

Full report
This Week
Bullish Opinions: 1 (1/0/0)
Previous Week
Neutral Opinions: 1
Two Weeks Ago
Neutral Opinions: Na
Three Weeks Ago
Neutral Opinions: Na

Analyzing the Most Important BNTX news

BioNTech Acquires CureVac in $1.25B Deal to Bolster Vaccine Portfolio

Jun 14, 2025
Trend: Bullish
Influence: 9
The acquisition of CureVac strengthens BioNTech's vaccine pipeline and R&D capabilities, particularly in mRNA technology. This strategic move positions the company for long-term growth, likely boosting investor confidence. The deal's significant size and sector relevance have a strong potential to positively impact BNTX's stock price in the short to medium term.

BioNTech Strengthens mRNA Leadership with $1.25B CureVac Acquisition

Jun 12, 2025
Trend: Bullish
Influence: 8
The acquisition of CureVac enhances BioNTech's dominance in mRNA technology and oncology, creating significant synergies in manufacturing and innovation. This strategic move positions BioNTech for growth in cancer therapies and infectious diseases, likely boosting investor confidence. While shares traded flat, the long-term implications could strongly enhance its market value and competitive positioning, making this deal impactful.

RFK Jr. Reshapes CDC Vaccine Panel with New Appointments

Jun 11, 2025
Trend: Bearish
Influence: 7
The removal of the previous CDC vaccine advisory panel and appointment of potentially more skeptical members could slow vaccine adoption timelines, directly impacting BioNTech's (BNTX) COVID-19 vaccine sales. While details are limited, the uncertainty and potential for reduced demand could lead to negative sentiment around BNTX's stock in the near term, particularly amidst changing regulatory stances.

Historical and forecast chart of BioNTech stock

The chart below shows the historical price of BioNTech stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the BioNTech stock price can be found in the table below.

Long-term forecasts by years.

BioNTech SE Analysts predictions review

BioNTech's recent acquisition of CureVac and its partnership with Bristol-Myers Squibb highlight strategic moves to diversify revenue streams and enhance its oncology pipeline. These initiatives reduce reliance on COVID-19 vaccine sales and improve its competitive positioning in mRNA therapeutics. While the CureVac acquisition offers promising synergies in R&D efficiencies and margin improvements, the Bristol-Myers collaboration faces speculative risks tied to clinical trial outcomes. Macro pressures like rising interest rates and tighter biotech valuations could weigh on near-term sentiment. Overall, medium-to-long-term prospects remain robust due to pipeline diversification and technological innovation, though short-term volatility persists.

BioNTech Expands Cancer Capabilities Through Strategic CureVac Acquisition

Trend: Bullish
Jun 12, 2025

The strategic acquisition of CureVac by BioNTech positions the company to enhance its technological capabilities in targeting cancer treatments. This deal brings complementary mRNA technology to BioNTech's pipeline, which has the potential to strengthen its competitive edge in therapeutic innovation. The author underscores the significance of this integration as a near-term catalyst for investor sentiment.

Merging Strategic Synergies to Address Market Needs

The acquisition also signals BioNTech’s commitment to diversifying its oncology portfolio, which could drive revenue growth and long-term operational sustainability. The author highlights that such diversification reduces reliance on COVID-19 vaccine sales, mitigating single-product risk and responding to evolving market demands.

Moreover, potential R&D efficiencies and cost savings from CureVac’s expertise may improve margins and accelerate commercialization timelines. As noted by the author, these operational improvements could further support the stock’s valuation trajectory in the medium term.


Analyst: Terry Chrisomalis
( Followers: 13457
Articles: 1488 )

BioNTech's Strategic Alliance with Bristol-Myers: Evaluating Growth Potential and Investment Value

Trend: Bullish
Jun 06, 2025

The strategic partnership between BioNTech and Bristol-Myers Squibb emphasizes synergistic growth opportunities, particularly in the field of oncology and immunotherapy advancements. The author highlights that this collaboration leverages BioNTech's expertise in mRNA technology and Bristol-Myers' expansive distribution network, a combination aimed at accelerating innovative treatments to market. This factor is likely to bolster investor sentiment around BNTX due to its potential to unlock new revenue streams.

BioNTech's fiscal discipline and recent R&D investments in expanding its therapeutic pipeline are other critical components of its growth narrative. The focus on diversifying its business model beyond COVID-19 vaccines, as argued by the author, reflects a proactive approach to securing sustainable long-term revenue, which could positively influence its stock's valuation over time.

Focusing on Market Differentiation

The article points out that BioNTech's competitive positioning within the high-growth mRNA therapeutics sector remains one of its strongest assets. Compared to its peers, its collaborative framework and robust intellectual property portfolio place it as a leader in an increasingly competitive market. This competitive edge bodes well for its market capitalization growth prospects in the medium to long-term horizon.

The valuation analysis underscores a cautious optimism, as BNTX's current pricing may undervalue its future growth potential, especially as its non-COVID-related initiatives contribute more meaningfully to revenue. While subject to macroeconomic risks and clinical trial outcomes, the alignment of strategic initiatives suggests the stock may be positioned to outperform in the coming quarters.


Analyst: Jonathan Weber
( Followers: 52517
Articles: 1948 )

Is BioNTech Overestimating BNT-327's Commercial Potential Amid Market Hype?

Trend: Neutral
Jun 04, 2025

BioNTech's collaboration with Bristol Myers revolves around BNT-327, an experimental oncology asset. The author suggests that while the partnership signals promise in expanding BioNTech's oncology pipeline, investor enthusiasm may prematurely price in speculative success. Given the clinical uncertainties in early-stage drug development, the near-term stock price impact could be disproportionately driven by sentiment rather than fundamentals.

Evaluating Market Expectations and Risks

The valuation surge tied to the BNT-327 deal reflects heightened expectations, but actual revenue realization may take years and is contingent on clinical milestones. The article asserts that an overhyped narrative could make the stock vulnerable to corrections if pipeline developments underperform or regulatory setbacks occur.

Additionally, the competitive oncology landscape complicates BNT-327's commercial success. The author points to numerous existing and emerging therapies targeting similar indications, which could limit BioNTech's market penetration and pricing power, bluntly reducing upside potential for shareholders.

Broader macroeconomic conditions and declining sentiment in biotech investing add external pressures on BioNTech's stock. While oncology remains a high-growth area, rising interest rates and investor preference for profitability over speculative growth could weigh on valuation in the near term.


Analyst: Edmund Ingham
( Followers: 13354
Articles: 1024 )
Mar 17, 2025
BioNTech's Oncology Expansion: A Promising Yet Risk-Assessed Opportunity
Trend: Neutral

BioNTech's strategic pivot toward oncology represents a bold diversification from its historical reliance on COVID-19 vaccine revenue streams. This shift positions the company in the burgeoning immunotherapy space, where advancements in personalized cancer medicines could unlock substantial long-term growth. However, the author, **[Author Name]**, emphasizes that such transformations in focus could entail near-term volatility as the company navigates high research and development costs.

The financial viability of BioNTech's oncology ventures is significantly influenced by its strong cash reserves and profitable operations during the pandemic. As highlighted, these factors provide the company with the capacity to invest intensively in clinical trials and partnerships, shielding it from immediate liquidity concerns.

Impact on Long-Term Growth and Stock Valuation

Market sentiment around BioNTech remains cautiously optimistic, supported by its innovative platform technologies and ongoing trial outcomes. While the oncology transition may heighten risk perception in the short term, the author contends that successful product launches could redefine investor confidence and drive future stock appreciation.

Analyst: Myriam Alvarez
( Followers: 2375
Articles: 283 )
Jan 23, 2025
BioNTech SE: Headwinds in Financials and Pipeline Challenges Suggest Caution
Trend: Bearish

A key factor influencing BioNTech SE's outlook is its waning financial performance, as revenue and profitability have significantly declined following the peak of COVID-19 vaccine demand. This suggests that the company's financials are heavily reliant on pandemic-related revenues, raising concerns about the sustainability of earnings in the near term. The continued erosion here could weigh on the stock price further if not counterbalanced by new revenue streams.

Another critical consideration is the uncertainty surrounding the company's product pipeline. Despite its efforts to diversify into oncology and other therapeutics, no highly compelling near-term catalysts have emerged. This lack of visibility into meaningful pipeline contributions adds another layer of risk to the investment thesis.

Pipeline and Market Dynamics: Core Investor Concerns

Additionally, BioNTech faces increased competition in both the mRNA technology space and the broader biopharmaceutical landscape. Rivals are rapidly innovating, which could dilute BioNTech's market share unless it establishes clear differentiation. This highly competitive environment, combined with ongoing macroeconomic uncertainty, can amplify pressure on the stock.

Lastly, valuation concerns may further temper investor sentiment. With the company's forward price-to-earnings and price-to-sales ratios still elevated relative to declining revenue streams, any failure to deliver new growth avenues could justify continued multiple compression in the stock valuation.

Analyst: Pinnacle Investment Analyst
( Followers: 1212
Articles: 133 )
Nov 06, 2024
BioNTech Q3 Results Highlight Growth Potential Amid Uncertainties
Trend: Neutral

BioNTech's recent quarterly earnings reveal a complex financial landscape characterized by revenue volatility due to declining COVID-19 vaccine demand. The performance underscores a key challenge for the company: the need to diversify its revenue streams and reduce dependency on pandemic-related products, which the author views as a pivotal factor for stock valuation in the near term.

Robust progress in the development of mRNA-based treatments and oncology pipelines suggests potential growth drivers in the long term. The author emphasizes this as a major upside, tempered by the high-risk nature of biotech R&D and the extended timelines needed for clinical trial validation and regulatory approval.

Short-Term Headwinds Still Present Opportunities

Operational cost optimization and management's focus on strategic partnerships could provide near-term resilience amidst revenue headwinds. The author identifies partnerships with pharma giants and expansion into adjacent markets as notable efforts to sustain investor confidence during an uncertain post-COVID environment.

Market sentiment remains cautious as the company navigates balancing R&D investment with profitability goals. As the author notes, this financial duress could lead to continued stock price stagnation unless breakthrough developments generate meaningful catalysts.

Analyst: Edmund Ingham
( Followers: 12877
Articles: 913 )
Oct 21, 2024
BioNTech's Dual Focus: Oncology Evolution and Strategic Potential
Trend: Neutral

BioNTech's pivot towards oncology appears to be a calculated move to diversify its revenue streams beyond its highly successful COVID-19 vaccine portfolio. The company's recent investments in cancer therapeutics emphasize long-term innovation, signaling a willingness to accept higher short-term R&D costs for potentially transformative products that could redefine its revenue mix.

Pipeline progression remains a critical indicator for investors, as any updates—both positive and negative—could significantly influence the stock price. The author notes that upcoming clinical trial results for key oncology candidates act as pivotal inflection points that could inject volatility into the stock, underscoring the high-risk, high-reward nature of the company’s strategy.

Broader Industry Dynamics

The competitive landscape in oncology is intensifying, with BioNTech attempting to carve out a niche in immune-oncology therapies. Strategically, its collaboration efforts and proprietary mRNA technology could provide differentiation, but the author points out that maintaining leadership will require continuous execution against well-funded competitors.

Valuation calls into question near-term upside potential, as current stock levels may already reflect optimism around past vaccine performance and the nascent oncology pipeline. However, the author's analysis indicates that execution success on early-stage candidates could unlock significant value, provided operational efficiencies are maintained amidst rising costs.

Analyst: Stephen Ayers
( Followers: 7833
Articles: 799 )
Sep 11, 2024
BioNTech: Discounted Valuation and Pipeline Diversity Signal Growth Potential
Trend: Bullish

BioNTech’s current valuation is significantly lower compared to its peers within the biotechnology sector, creating an opportunity for long-term investors. The undervaluation appears to reflect investor concerns about post-COVID-19 revenue declines, but the company’s broad therapeutic pipeline mitigates this risk by diversifying its revenue base.

Pipeline Innovation and Competitive Position

The company’s robust pipeline of mRNA and immunotherapy-based treatments demonstrates strong innovation potential. Notably, advancements in oncology and other infectious diseases highlight its ability to diversify beyond reliance on COVID-19 vaccine revenues, adding to investor confidence in its future growth trajectory.

Meanwhile, its partnership strategy—most prominently with Pfizer—strengthens its global reach and operational capability. This enhances the ability to commercialize new therapies swiftly, further contributing to its competitive advantage, particularly in the precision medicine space.

Macro factors, including fluctuations in vaccine-related demand and evolving regulatory environments, remain potential headwinds. However, the company’s consistent R&D investments and IP portfolio position it well to navigate these challenges, making it an attractive option in the biotech sector even amidst market volatility.

Analyst: Larry Ramer
( Followers: 752
Articles: 65 )
Aug 20, 2024
BioNTech: ADC Development Gains Momentum with Regulatory Clearance
Trend: Bullish

BioNTech's recent removal of a clinical hold on its antibody-drug conjugate (ADC) development program represents a pivotal step forward in expanding its oncology pipeline. This regulatory clearance not only accelerates research timelines but also reinforces investor confidence in the company's capacity to innovate in targeted cancer therapies, particularly given the growing market potential for ADCs.

The company's strategic emphasis on diversifying revenue streams beyond COVID-19 vaccine sales emerges as a key factor for long-term growth resiliency. Despite declining pandemic-related revenues, BioNTech's progress in oncology therapies suggests a proactive approach to addressing market shifts and sustaining investor interest.

Broader Industry Relevance and Impact on Valuation

Additionally, BioNTech's positioning within the broader biotech space remains competitive, as the advancement of its ADC program aligns with favorable industry trends such as increased demand for precision medicine. This development could improve the company's valuation in the near term as investors factor in its potential to capture market share in an emerging high-growth niche.

Macroeconomic factors, however, pose potential headwinds, particularly rising interest rates and economic uncertainty, which could pressure capital-intensive biotech firms like BioNTech. Nonetheless, the ADC progress provides a strong narrative for value creation that may mitigate broader market risks in the short to medium term.

Analyst: Terry Chrisomalis
( Followers: 13156
Articles: 1392 )

Comprehensive Analysis of BioNTech (BNTX) Stock Market Performance


Our multifaceted analysis of BioNTech's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:

  • When should I take profit in BioNTech stock?
  • When should I record a loss on BioNTech stock?
  • What are analysts' forecasts for BioNTech stock?
  • What is the future of BioNTech stock?

We forecast BioNTech stock performance using neural networks based on historical data on BioNTech stocks.

BioNTech SE is a German biotechnology company that develops and manufactures active immunotherapeutic agents for an individual approach to the treatment of serious diseases. The company is investigating messenger RNA (mRNA) -based drugs for use as individualized immunotherapy for cancer, as vaccines against infectious diseases and as protein replacement therapy for rare diseases, as well as developed cell therapy, new antibodies and small molecules, immunomodulators, as options cancer treatment. The company has developed an intravenous mRNA-based human therapeutic drug to bring individualized mRNA-based cancer immunotherapy to clinical trials and establish its own manufacturing process.

BioNTech SE News influencing stock rates

As of now, Panda has combed through 9 news items directly related to BNTX from the last 30 days. Out of these, 3 clearly showcase a bullish trend, while 3 display bearish tendencies, and 3 events are neutral.

The strength of the bullish trend outpaces the bearish sentiments by 1.18 times, indicating that the news backdrop is positively influencing the company’s stock price in the current outlook.

The news analyzed fell within the period from May 30, 2025, to Jun 14, 2025.

βeta
Jun 10, 2025

RFK Jr.'s CDC Shake-Up Leaves Vaccine Makers Unmoved

Trend: Neutral
Influence: 3
Despite RFK Jr.'s removal of CDC advisory panel members, vaccine makers like BioNTech (BNTX) traded flat, as market sentiment hasn't shifted decisively. The decision introduces regulatory uncertainties, but it lacks immediate impact on BioNTech's operations or stock price. The stock remains stable unless further significant policy changes materialize under the current administration.
Jun 09, 2025

RFK Jr. Revamps CDC Vaccine Advisory Panel Amid Conflict of Interest Allegations

Trend: Neutral
Influence: 3
This post highlights RFK Jr.'s overhaul of vaccine practices and advisory panels at the CDC. While this signals potential scrutiny on vaccine manufacturers, its direct impact on BNTX appears limited. Regulatory uncertainty might slightly weigh on sentiment, but no immediate change in product approval or operations for BNTX is evident, keeping influence on stock price minimal in the near term.
Jun 05, 2025

Leadership Void at CDC Sparks Public Health Concerns

Trend: Neutral
Influence: 2
The report on CDC's leadership uncertainty doesn't directly link to BNTX (BioNTech). While the CDC's role impacts vaccine deployment, this news primarily concerns internal U.S. agency operations rather than vaccine production or market demand. Therefore, the influence on BNTX's stock is minimal, and the trend remains neutral with a weak potential for immediate stock price impact.
Jun 04, 2025

CDC Advisor Resignation Sparks Uncertainty Over COVID Vaccine Guidance

Trend: Bearish
Influence: 7
The resignation highlights uncertainties related to the CDC's evolving COVID-19 immunization policies and potential diminishing recommendations for vaccines, including those co-developed by BioNTech (BNTX). Such regulatory shifts may negatively impact market sentiment regarding vaccine producers, including BNTX, leading to short-term volatility and a bearish outlook for the stock's performance in the near future.
Jun 02, 2025

Bristol Myers Squibb Bets Big on BioNTech with $11.1B Immunotherapy Deal

Trend: Bullish
Influence: 8
This licensing deal with Bristol for BNT327 highlights confidence in BioNTech's pipeline and expands its oncology focus. The hefty deal value suggests significant potential for the bispecific antibody, which could bring substantial revenue if successful. Positive market sentiment is likely, as partnerships of this scale often reflect strong endorsement of a biotech company's R&D strengths.
May 30, 2025

CDC Revises Child Immunization Guidance Post RFK Jr. COVID Remarks

Trend: Bearish
Influence: 7
The CDC's shift to shared clinical decision-making for pediatric COVID-19 vaccinations introduces uncertainty regarding demand for BioNTech's vaccines. This regulatory adjustment, coupled with RFK Jr.'s claims, could dampen public confidence and vaccine uptake, negatively impacting sales. Market sentiment may weigh on BNTX stock in the short-term, reflecting concerns over reduced long-term revenue prospects.
May 23, 2025

FDA Recommends JN.1 COVID Shot: Boost for BioNTech’s Vaccine Plans

Trend: Bullish
Influence: 7
The FDA's recommendation to update COVID vaccines to target the JN.1 strain positively impacts BioNTech (BNTX), as its partnership with Pfizer enhances its readiness to deliver updated shots. This highlights strong positioning in vaccine innovation, likely boosting investor confidence and near-term stock price momentum. However, potential competitive dynamics with Moderna and Novavax could moderate gains.
May 21, 2025

RFK Jr. Targets Vaccines and Food Chemicals in New Health Report

Trend: Neutral
Influence: 4
The report focusing on vaccine trials and food chemicals may stir public discourse but lacks specific emphasis on BNTX directly. Insights into vaccine safety debates could indirectly influence sentiment on pharmaceutical vaccine developers like BNTX, but the impact remains limited without explicit critique or scientific evidence targeting their products.
May 21, 2025

BioNTech Launches $1.3B UK R&D Partnership Boosting Innovation

Trend: Bullish
Influence: 8
BioNTech's strategic UK investment enhances its innovation capacity, signaling growth potential in R&D and global expansion. Such long-term commitments positively influence investor sentiment, as they showcase a robust pipeline and government alignment, likely driving stock up. This impactful development could increase confidence in BioNTech's competitiveness beyond COVID-related products, ensuring sustained relevance in the biopharma industry.
May 17, 2025

FDA Approves Novavax Shot for Seniors: New Competition for COVID Vaccine Market

Trend: Bearish
Influence: 7
The FDA approval of Novavax's protein-based vaccine introduces new competition to the COVID-19 vaccine market. Considering BNTX (BioNTech) relies heavily on its mRNA technology-based vaccine portfolio, this development could negatively impact its market share and revenue growth, especially among senior demographics. The high influence score reflects the significant potential for Novavax's approval to reshape competitive dynamics.

Trending Themes in the Healthcare Sector

BioNTech daily forecast for a month

Date Target Pes. Opt. Vol., %
Jun 24 111.04 106.31 113.37 6.64
Jun 25 112.50 110.21 117.30 6.43
Jun 26 113.92 112.42 117.27 4.32
Jun 27 110.30 106.79 112.42 5.27
Jun 28 114.67 109.99 117.01 6.38
Jun 29 113.84 112.27 117.05 4.26
Jun 30 116.78 111.66 120.28 7.72
Jul 01 116.92 113.20 119.93 5.95
Jul 02 112.29 110.13 115.66 5.02
Jul 03 108.11 105.97 110.71 4.47
Jul 04 109.80 105.52 111.84 5.99
Jul 05 110.92 107.72 116.17 7.85
Jul 06 115.71 110.43 120.98 9.56
Jul 07 121.05 116.91 125.41 7.27
Jul 08 125.48 122.77 129.40 5.40
Jul 09 123.30 118.79 125.59 5.73
Jul 10 125.45 120.55 127.03 5.37
Jul 11 131.69 128.22 133.59 4.19
Jul 12 132.48 127.64 137.57 7.78
Jul 13 125.01 121.86 129.44 6.22
Jul 14 128.69 126.76 130.31 2.80
Jul 15 126.14 121.75 129.77 6.59
Jul 16 133.71 130.58 139.56 6.88
Jul 17 141.01 135.00 144.65 7.14
Jul 18 146.51 140.79 148.88 5.74
Jul 19 155.21 149.44 161.54 8.10
Jul 20 151.58 145.67 157.49 8.12
Jul 21 146.67 143.59 152.30 6.07
Jul 22 139.19 135.43 141.36 4.38
Jul 23 130.84 127.93 133.66 4.48

BioNTech Daily Price Targets


BioNTech Stock Forecast 06-24-2025.

Forecast target price for 06-24-2025: $111.04.
Positive dynamics for BioNTech shares will prevail with possible volatility of 6.229%.
Pessimistic target level: 106.31
Optimistic target level: 113.37

BioNTech Stock Forecast 06-25-2025.

Forecast target price for 06-25-2025: $112.50.
Positive dynamics for BioNTech shares will prevail with possible volatility of 6.042%.
Pessimistic target level: 110.21
Optimistic target level: 117.30

BioNTech Stock Forecast 06-26-2025.

Forecast target price for 06-26-2025: $113.92.
Positive dynamics for BioNTech shares will prevail with possible volatility of 4.138%.
Pessimistic target level: 112.42
Optimistic target level: 117.27

BioNTech Stock Forecast 06-27-2025.

Forecast target price for 06-27-2025: $110.30.
Negative dynamics for BioNTech shares will prevail with possible volatility of 5.004%.
Pessimistic target level: 106.79
Optimistic target level: 112.42

BioNTech Stock Forecast 06-28-2025.

Forecast target price for 06-28-2025: $114.67.
Positive dynamics for BioNTech shares will prevail with possible volatility of 5.998%.
Pessimistic target level: 109.99
Optimistic target level: 117.01

BioNTech Stock Forecast 06-29-2025.

Forecast target price for 06-29-2025: $113.84.
Negative dynamics for BioNTech shares will prevail with possible volatility of 4.085%.
Pessimistic target level: 112.27
Optimistic target level: 117.05

BNTX (BNTX) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jul. 111.88 107.58 119.13 9.69
Aug. 108.25 103.32 110.85 6.80
Sep. 107.60 100.50 117.55 14.50
Oct. 110.32 103.30 113.63 9.09
Nov. 112.43 108.52 121.61 10.76
Dec. 109.33 104.21 119.70 12.93

BioNTech forecast for this year


BioNTech Stock Prediction for Jul 2025

An uptrend is forecast for this month with an optimal target price of $111.879. Pessimistic: $107.58. Optimistic: $119.13


BioNTech Stock Prediction for Aug 2025

An downtrend is forecast for this month with an optimal target price of $108.254. Pessimistic: $103.32. Optimistic: $110.85


BioNTech Stock Prediction for Sep 2025

An downtrend is forecast for this month with an optimal target price of $107.604. Pessimistic: $100.50. Optimistic: $117.55


BioNTech Stock Prediction for Oct 2025

An uptrend is forecast for this month with an optimal target price of $110.316. Pessimistic: $103.30. Optimistic: $113.63


BioNTech Stock Prediction for Nov 2025

An uptrend is forecast for this month with an optimal target price of $112.434. Pessimistic: $108.52. Optimistic: $121.61


BioNTech Stock Prediction for Dec 2025

An downtrend is forecast for this month with an optimal target price of $109.331. Pessimistic: $104.21. Optimistic: $119.70



BioNTech (BNTX) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 120.35 116.74 127.86 8.70
Feb 122.95 120.00 126.05 4.80
Mar 125.61 116.86 131.94 11.42
Apr 124.40 113.65 136.34 16.64
May 113.06 106.54 123.50 13.73
Jun 107.90 101.30 118.26 14.34
Jul 119.29 111.85 122.44 8.65
Aug 119.15 109.71 128.02 14.30
Sep 121.73 112.08 125.52 10.71
Oct 125.08 114.88 134.54 14.62
Nov 137.09 132.49 146.80 9.75
Dec 140.88 132.76 149.16 10.99

BioNTech (BNTX) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 140.37 131.44 147.11 10.65
Feb 134.64 126.73 141.43 10.40
Mar 129.96 126.21 141.19 10.60
Apr 125.12 115.06 137.13 16.10
May 131.43 120.86 139.79 13.54
Jun 136.95 127.09 147.47 13.82
Jul 153.22 148.25 164.80 10.04
Aug 163.51 152.13 169.20 10.09
Sep 183.14 171.49 187.97 8.77
Oct 161.16 148.78 172.18 13.59
Nov 163.29 154.86 167.40 7.49
Dec 154.67 150.40 163.95 8.26

BioNTech information and performance

BioNTech Address

AN DER GOLDGRUBE 12, MAINZ, DE

Market Capitalization: 23 032 052 000 $

Market capitalization of the BioNTech SE is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of BNTX shares in the company outstanding by the market price of one share.

EBITDA: -1 019 900 032 $

EBITDA of BioNTech is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: 0.0449

Price/earnings to growth

DPS: None

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: None

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -3.58

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: -0.432
Quarterly Revenue Growth YOY: -0.026
Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 7.04

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 2.341

Enterprise Value (EV) /Revenue

EV To EBITDA: 110.81

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 240393000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

BioNTech (BNTX) stock dividend

BioNTech last paid dividends on 06/02/2022. The next scheduled payment will be on 06/17/2022. The amount of dividends is $None per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.

Last Split Factor:

Last Split Date: 01/01/1970

Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.

For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.

FAQ (Frequently Asked Questions about BioNTech Stock)

Should I Buy BioNTech Shares in 2025 year?

The maximum forecasted share price for next year is $140.88, which is $34.35 higher than the current stock price. By investing in BioNTech shares today for a one-year period, you could achieve a profit of 32.24%. With an investment horizon of up to two years, the target share price is $183.14. resulting in a profit of 71.91% ($76.61 per share).

Does BioNTech pay dividends?

No, it does not

Which economic sector do BioNTech's shares belong to?

BioNTech's shares belong to the "Healthcare" sector of economic.

Which other securities belong to the same sector as BioNTech's shares?

You can view all the stocks that are part of the same sector as BioNTech's shares in the Healthcare section.


Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.